Metrics Files Patent for Controlled-Release System
Metrics Files Patent for Controlled-Release System
Scientists at Metrics, Inc. (Greenville, NC) have developed an extended-release drug delivery platform for tablets requiring zero-order or near-zero–order in vitro dissolution.
According to Metrics's development scientist Brian Woodall, the delivery system is based on a unique ratio of FDA-approved, National Formulary-grade excipients as well as a minor thin-film coating (3–5%). The technology, currently the subject of a provisional patent application, is similar to a matrix tablet system in that it depends on the behavior of the selected polymers to swell, dissolve, and form a gel-like mass at a specific rate, which enables a controlled and steady release. The film coating prevents initial dose-dumping when the tablet is dropped into a dissolution vessel, thereby extending the release rate. The manufacture of the system involves dry-blending the active ingredient, compressing the tablet, and applying the film coating.
Woodall and co-developer Brad Gold, Metrics's director of pharmaceutical development and new technologies, report the delivery mechanism is pH-independent, suitable for both low and relatively high-dose active ingredients, as well as for water-soluble and -insoluble compounds that are hydrophobic or hydrophilic. The company plans to present more information about the technology at the American Association of Pharmaceutical Scientists annual meeting in November.
–Maribel Rios
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
